Abstract：
Progestin-only pills (POPs) have emerged as a crucial contraceptive option for women, particularly those contraindicated to oestrogens. This opinion paper introduces two new indices, the Inhibition Ratio (I.R.) (cyclical and daily) and the Transformation Index (T.I.), to evaluate and compare the efficacy and clinical behaviour of modern POPs. The I.R. quantifies the ratio between the progestin dosage in a POP and the minimum dose required to inhibit ovarian function, providing insights into contraceptive efficacy. The T.I., on the other hand, assesses its clinical impact by considering the ratio between the total progestin dose and the dose required to induce endometrial luteinising changes. Both indices thus offer valuable tools for comparing progestins even at significantly different dosages and regimens, providing information on clinical characteristics and drug effects. The newest formulations of POPs (Desogestrel 28 and Drospirenone 24 + 4) have demonstrated higher I.R. and T.I. in comparison to older versions, indicating significant improvements in contraceptive efficacy and clinical impact with better menstrual cycle control. We believe that using these indices will ensure a more informed and personalised choice of progestin not only for contraceptive purposes but also for therapeutic use in gynaecology. The future goal is to develop other progestins with even more advantageous I.R. and T.I., ensuring the best contraceptive efficacy with fewer side effects, even in women at risk (obese, etc.).
The Inhibition Ratio (I.R.) (cyclical and daily) and the Transformation Index (T.I.) are two new proposed indexes to evaluate and compare the efficacy and clinical behaviour of modern and future POPs.
The Inhibition Ratio (I.R.) (cyclical and daily) and the Transformation Index (T.I.) are two new proposed indexes to evaluate and compare the efficacy and clinical behaviour of modern and future POPs.
摘要：
仅含孕激素的药丸（POPs）已成为女性的重要避孕选择，特别是那些禁忌雌激素。这篇观点文件介绍了两个新的指数，抑制率(I.R.)(周期和每日)和转化指数(T.I.)，评估和比较现代POPs的疗效和临床行为。I.R.量化POP中孕激素剂量与抑制卵巢功能所需的最小剂量之间的比率，提供避孕功效的见解。T.I.，另一方面,通过考虑孕激素总剂量与诱导子宫内膜黄体化变化所需剂量之间的比率来评估其临床影响。因此，这两个指数提供了有价值的工具，即使在显著不同的剂量和方案比较孕激素。提供有关临床特征和药物作用的信息。与旧版本相比，持久性有机污染物的最新配方（Desogestrel28和Drospirenone244）显示出更高的I.R.和T.I.。表明在更好的月经周期控制下，避孕效果和临床效果显着改善。我们相信，使用这些指数将确保孕激素的更明智和个性化的选择，不仅用于避孕目的，而且用于妇科的治疗用途。未来的目标是开发具有更有利的I.R.和T.I.的其他孕激素，确保最佳避孕效果，副作用少，即使在有风险的女性中(肥胖，等。).
抑制率（I.R.）（周期和每日）和转化指数（T.I.）是两个新提出的指标，用于评估和比较现代和未来POPs的疗效和临床行为。
抑制率（I.R.）（周期和每日）和转化指数（T.I.）是两个新提出的指标，用于评估和比较现代和未来POPs的疗效和临床行为。
